CYPH Cypherpunk Technologies Inc.
USHealthcareAs of 2026-08-17
Why CYPH matters now
Cypherpunk Technologies Inc. (CYPH) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.71 with +9.52% on the session and $75.1M in market capitalization; recent performance reads 1-month -32.18% and YTD -36.28%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-77.2M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -102.2%.
The latest indexable market news headline is "Cypherpunk Technologies Reports Second Quarter 2026 Financial Results" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.50; recent insider activity includes Mirabelli Christopher filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.47
P/S
0.00
EV/EBITDA
-1.19
DCF Value
$2.16
FCF Yield
-102.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.9%
ROA
-65.1%
ROIC
-35.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-77.2M | $-0.46 |
| Q4 2025 | $0.00 | $40.2M | $0.92 |
| FY 2025 | $0.00 | $4.8M | $0.07 |
| Q3 2025 | $0.00 | $-3.3M | $-0.08 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.50
Target (Median)
$5.50
Target Range
$5.50 - $5.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.02
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.